Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT)
Status:
Completed
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
The primary objective is to test the hypothesis that, compared with placebo, therapy with
Subcutaneous (SQ) GLP-1 agonist in the post-Acute Heart Failure Syndrome (AHFS) discharge
period will be associated with greater clinical stability at six months as assessed by a
composite clinical endpoint.